Macrolides may cause severe drug-interactions due to the inhibition of metabolizing enzymes. Transporter-mediated uptake of drugs into cells [e.g. by members of the human organic anion transporting polypeptide (OATP) family] is a determinant of drug disposition and a prerequisite for subsequent metabolism. However, it has not been systematically studied, whether macrolides are also inhibitors of uptake transporters thereby providing an additional mechanism of drug-interactions.
Introduction
Macrolide antibiotics (e.g. erythromycin, clarithromycin) can cause severe drug interactions by increasing plasma concentrations of simultaneously administered compounds. The major mechanism underlying these drug interactions is believed to be inhibition of the major drug metabolizing enzyme CYP3A4 in small intestine and liver (Ito et al., 2003; Polasek and Miners, 2006; Wrington and E.Thummel, 2000) .
Published data indicate that certain macrolides are also inhibitors of the apically / luminally localized drug efflux pump P-glycoprotein (Eberl et al., 2005; Kim et al., 1999; Marzolini et al., 2004) . By inhibition of P-glycoprotein function they increase drug absorption from the gut lumen and decrease biliary elimination and renal secretion of concomitantly administered drugs such as the cardiac glycoside digoxin (Rengelshausen et al., 2003) . This in turn leads to increased drug concentrations and drug toxicity.
A newly recognized, additional determinant of drug disposition are uptake transporters of the OATP (SLCO) family (Hagenbuch and Meier, 2004; König et al., 2006) . Members of the OATP family transport a wide range of drugs including HMGCoA reductase inhibitors (cerivastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin), benzylpenicillin, digoxin, fexofenadine, methotrexate, and rifampicin (Hagenbuch and Meier, 2003; König et al., 2006) . OATP1B1 and OATP1B3 are expressed in the basolateral membrane of hepatocytes and mediate the uptake of endogenous substances and drugs from the portal venous blood into the liver. The importance of uptake transporters for drug disposition has been demonstrated analyzing genetic alterations in the SLCO1B1 gene encoding human OATP1B1.
Several polymorphisms or haplotypes have been associated with reduced drug uptake activity in vitro (Iwai et al., 2004; Kameyama et al., 2005; Michalski et al., 2002; Tirona et al., 2001) . Furthermore, it has been shown in vivo that the basepairThis article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on February 12, 2007 as DOI: 10.1124 at ASPET Journals on April 6, 2017 dmd.aspetjournals.org Downloaded from
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5 exchange T521C, resulting in an amino acid exchange Val174Ala, was related to increased drug concentrations [e.g. for atrasentan (Katz et al., 2006) , fexofenadine (Niemi et al., 2005b) , pitavastatin (Chung et al., 2005) , pravastatin Nishizato et al., 2003) , simvastatin acid , repaglinide (Niemi et al., 2005a) , and rosuvastatin (Lee et al., 2005) ].
Since alterations in the OATP1B1 protein can be associated with a change in transport activity for certain drugs, uptake transporters may also be a mechanism for drug-drug interactions. For instance, it has been demonstrated that the macrolides clarithromycin and erythromycin significantly increase pravastatin plasma concentrations (Jacobson, 2004; Product-information, Pravasin ® protect, 2005 ).
Since pravastatin is not metabolized by cytochrome P450 enzymes, uptake transporters may account for this drug-drug interaction. In spite of the increasingly recognized role of OATP uptake transporters for drug disposition, it has not been systematically studied whether macrolides are inhibitors of the uptake of concomitantly administered drugs mediated by OATPs and thereby providing a new additional mechanism of macrolide-induced drug interactions.
Therefore, using HEK293 cells stably expressing the human uptake transporters
OATP1B1 or OATP1B3, we tested in the present study the influence of macrolide antibiotics on the OATP1B1-and OATP1B3-mediated uptake of organic anions and drugs.
This article has not been copyedited and formatted. The final version may differ from this version. Methanol (hypergrade quality), n-hexane (p.a.), acetonitrile (hypergrade quality), and acetic acid (supra pure quality) were purchased from Merck KGaA (Darmstadt, Germany). Diethyl ether (99.8 % purity), ammonium acetate (p.a.), and ibuprofen were obtained from Sigma-Aldrich Chemie GmbH (Taufkirchen, Germany).
Cell culture and transfection
Human embryonic kidney (HEK293) cells were cultured in minimum essential medium; containing 10 % heat inactivated fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin, at 37 °C and 5 % CO 2 . The cells were routinely subcultivated by trypsinization using trypsin (0.05 %) -EDTA (0.02 %) solution. All cell The cells (HEK-control, HEK-OATP1B1, and HEK-OATP1B3) were grown to confluence for 3 days and induced with 10 mM sodium butyrate (Merck KGaA, Darmstadt, Germany) for 24 h prior the uptake and immunoblot experiments to obtain higher levels of the recombinant proteins (Cui et al., 1999) .
Immunoblot Analysis
Pelleted HEK293 cells expressing the respective protein were resuspended in protein storage buffer (100 mM Tris-HCl, 1 mM EDTA, pH 7.4) containing protease inhibitors 
Uptake assays
Before starting the uptake experiments the cells were washed with pre-warmed (37 °C) uptake buffer (142 mM NaCl, 5 mM KCl, 1 mM K 2 HPO 4 , 1.2 mM MgSO 4 , 1.5 mM CaCl 2 , 5 mM glucose, and 12.5 mM HEPES, pH 7.3).
The [ 3 H]BSP was dissolved in uptake buffer and unlabeled BSP was added to the final concentration of 0.05 µM and 1 µM BSP for studies with HEK-OATP1B1 and HEK-OATP1B3, respectively. To characterize the macrolides as inhibitors they were added in increasing concentrations (up to 500 µM). The cells were incubated with the test solution at 37 °C for 10 minutes as described previously (Letschert et al., 2004; Michalski et al., 2002) . Subsequently, the cells were washed three times with ice-cold uptake buffer. After lysing the cells with 0.2 % sodium dodecyl sulfate (SDS) the intracellular accumulation of radioactivity was calculated by liquid scintillation counting (Perkin Elmer Life Sciences GmbH, Rodgau, Jügesheim, Germany) and the For experiments with pravastatin as substrate, 50 µM pravastatin was dissolved in the uptake buffer. In addition, 10 µM or 100 µM of each macrolide was added. The uptake assay was performed as described above except for the determination of the intracellular pravastatin accumulation: after lysing the cells with 0.2 % SDS the amount of intracellular pravastatin was determined by LC/MS/MS.
LC/MS/MS assay for pravastatin
Samples were prepared by adding 100 µl internal standard solution (200 ng/ml ibuprofen in eluent) to 100 µl of the cell lysates. The injected volume was 30 µl.
LC/MS/MS analysis was performed using a Sciex API 4000 TM (Applied Biosystems, (50/50 v/v) was used as the mobile phase. The flow rate was set at 0.2 ml/min. The retention time of pravastatin was 1.2 min and 1.4 min for the internal standard. The peak area ratio of pravastatin to the internal standard was calculated using Analyst 1.4.2 (Applied Biosystems, Foster City, USA) software. The lower limit of quantification was 0.5 ng/ml. A calibration curve was constructed using 1/X-weighted linear regression between spiked cell lysate concentrations and the measured ratios.
The calibration curves were linear over the range 0.5 -30 ng/ml with the mean quality controls, blank, and double blank samples were prepared in the same manner. The intra-day coefficient of variation was 2.14 % at 0.5 ng/ml, 1.60 % at 1 ng/ml, 6.93 % at 10 ng/ml, 5.32 % at 30 ng/ml (n = 4 to 5).
Data Analysis
The OATP1B1-and OATP1B3-mediated net uptake was obtained by subtracting the uptake in vector GraphPad Software, San Diego, USA). The IC 50 value is the concentration at which half of the substrate uptake was inhibited.
Statistical Analysis
The experiments were repeated at least 4 times. All data are presented as mean ± 
Results

BSP uptake in HEK-OATP1B1 and HEK-OATP1B3 cells
The prerequisite for analyzing the inhibitory potency of drugs on OATP1B1-and OATP1B3-mediated uptake is the availability of stably transfected cells expressing the recombinant protein in high amounts. Therefore, HEK293 cells were stably transfected with the SLCO1B1 cDNA and the SLCO1B3 cDNA and selected for a high expression of the respective uptake transporter. The protein expression of the selected cell clones has been analyzed using the OATP1B1-specific antibody pESL (König et al., 2000a ) and the OATP1B3-specific antibody pSKT (König et al., 2000b) .
This analysis demonstrated a high protein expression in the HEK-OATP1B1 and HEK-OATP1B3 cells (Fig. 1A) .
Uptake mediated by OATP1B1 or OATP1B3 was analyzed using the prototypic tritium-labeled substrate sulfobromophthalein (BSP). BSP was shown to be a high affinity substrate for both OATP1B1 and OATP1B3 with K m values of 140 nM (Cui et al., 2001b) 
Inhibition of OATP1B1-mediated BSP uptake by macrolides
Uptake experiments have been carried out as described with adding different concentrations of the respective macrolide. Interestingly, all investigated macrolides except azithromycin showed a clear doses-dependent inhibition of OATP1B1-mediated BSP uptake into HEK-OATP1B1 cells (Fig. 2) . Azithromycin has been analyzed up to a concentration of 500 µM and only at this high concentration a slight decrease in BSP uptake was observed ( Fig. 2A) . Erythromycin also has a high IC 50
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2B, D , and E). Taken together, clarithromycin, erythromycin, roxithromycin, and telithromycin were identified to inhibit the OATP1B1-mediated BSP transport.
Inhibition of OATP1B3-mediated BSP uptake by macrolides
A similar experimental setup was used to analyze the inhibitory effect of macrolides on OATP1B3-mediated BSP uptake. As shown for the inhibition of OATP1B1-mediated uptake azithromycin did not inhibit the uptake mediated by the OATP1B3 protein (Fig. 3A) . All other investigated macrolides inhibited the OATP1B3-mediated BSP uptake ( Fig. 3B -E ). Telithromycin was a potent inhibitor for OATP1B3-mediated uptake with an IC 50 value of 11 ± 0.3 µM (Fig. 3E) . The macrolides erythromycin, clarithromycin, and roxithromycin showed inhibitory potency with IC 50
values of 34 ± 14 µM, 32 ± 7 µM, and 37 ± 6 µM, respectively ( Fig. 3B -D) .
Interestingly, the calculated IC 50 values for clarithromycin, erythromycin, roxithromycin, and telithromycin were determined to be lower than the respective IC 50 values for OATP1B1-mediated uptake.
OATP1B1-and OATP1B3-mediated pravastatin uptake and inhibition by macrolides
To test whether macrolides are also inhibitors for the OATP1B1-and OATP1B3-mediated uptake of pravastatin, we performed pravastatin uptake and inhibition experiments. Pravastatin is a known substrate for OATP1B1 (K m value of 34 µM; (Hsiang et al., 1999) . We confirmed that pravastatin is transported by OATP1B1 with a significantly higher uptake in HEK-OATP1B1 cells (4.5 pmol x mg protein -1 x min -1 ) compared to HEK-control cells (0.8 pmol x mg protein -1 x min -1 ) (Fig. 4A) .
Furthermore, we could demonstrate for the first time that pravastatin is also a This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 4B) .
Clarithromycin, erythromycin, and roxithromycin significantly inhibited the uptake of pravastatin in HEK-OATP1B1 cells (Fig. 5A) . Addition of 10 µM of clarithromycin or roxithromycin resulted in a reduced intracellular accumulation of pravastatin to 64 % and 65 % compared to the control experiments without macrolides (Fig. 5A ).
Clarithromycin (100 µM), a potent inhibitor of the OATP1B1-mediated BSP uptake, led to a reduction to 24 % intracellular accumulation of pravastatin compared to the control experiments. As for BSP, azithromycin did not inhibit the transporter-mediated uptake of pravastatin. In contrast, telithromycin which was a moderate inhibitor for BSP uptake was not significantly affecting the uptake of pravastatin (Fig. 5A ) and showed a moderate uptake inhibition only at the high concentration of 100 µM.
At low macrolide concentrations (10 µM) erythromycin and roxithromycin inhibited OATP1B3-mediated pravastatin uptake. The addition of 100 µM clarithromycin, erythromycin, roxithromycin, and telithromycin reduced the pravastatin uptake to 37 %, 36 %, 52 %, and 19 %, respectively (Fig. 5B) . Interestingly, telithromycin did not inhibit the uptake of pravastatin at the low concentration whereas the higher concentration significantly inhibited the uptake. Moreover, a slight but not significant transport activation by low clarithromycin and telithromycin concentrations could be observed. In accordance with the BSP inhibition assay azithromycin was the only macrolide showing no inhibition among the tested macrolides (Fig. 5B ).
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Discussion
In this study we focused on the analysis of the interaction of several macrolide / ketolide antibiotics with the transport of the organic anion BSP and the HMG-CoA reductase inhibitor pravastatin mediated by the hepatocellular uptake transporters OATP1B1 and OATP1B3. Using newly established HEK cells recombinantly expressing human OATP1B1 and OATP1B3 (Fig. 1) we found a concentrationdependent inhibition of BSP uptake both in HEK-OATP1B1 and HEK-OATP1B3 cells for all macrolides (except from azithromycin) and for the ketolide telithromycin. IC 50 values were considerably smaller for the uptake inhibition of OATP1B3 than for OATP1B1 (Figs. 2 and 3 ). Additionally to the inhibition studies with the prototypic substrate BSP we have investigated the influence of macrolides and the ketolide telithromycin on the uptake of the HMG-CoA reductase inhibitor pravastatin. We demonstrated OATP1B1-mediated pravastatin uptake into HEK-OATP1B1 cells as described earlier (Hsiang et al., 1999) . Furthermore to the best of our knowledge, we determined for the first time that pravastatin uptake is mediated by the second major hepatocyte OATP family member OATP1B3 (Fig. 4) . This transporter-mediated pravastatin uptake could be inhibited by co-administration of clarithromycin, erythromycin, and roxithromycin. In the case of OATP1B3, telithromycin was a potent inhibitor for BSP uptake, however, a strong inhibition of pravastatin uptake was observed only at high concentration (100 µM) of telithromycin. Clarithromycin, erythromycin, and roxithromycin inhibited both OATP1B1-and OATP1B3-mediated BSP and pravastatin uptake. On the other hand, azithromycin had no effect on BSP or on pravastatin uptake. Furthermore, transport of cerivastatin (Shitara et al., 2003) , pravastatin (Hsiang et al., 1999) , and rosuvastatin (Schneck et al., 2004) has been shown for OATP1B1
whereas OATP1B3 is able to mediate the uptake of digoxin (Kullak-Ublick et al., 2001 ). Due to these substrate spectra and their localization between portal venous blood and important drug metabolizing enzymes (e.g. CYP3A4) expressed in hepatocytes, uptake transporters are increasingly recognized as important factors in the directed elimination of drugs out of the body. Their presence can be a prerequisite for substances to enter hepatocytes and getting metabolized prior their elimination over the canalicular membrane into bile. Modification of uptake rates e.g.
by drug competition, therefore, may cause drug-drug interactions by lowering the uptake rate of one drug followed by increased blood concentrations due to reduced hepatic metabolism and / or decreased biliary elimination.
Inhibition of cytochrome P450 isoenzymes is one established mechanism of drugdrug interactions. Multiple studies have demonstrated that macrolides are potent inhibitors of CYP3A4 and therefore can increase the plasma concentration of coadministered drugs that are CYP3A4 substrates (Niemi et al., 2001 ). Druginteractions have also been reported between macrolides and some HMG-CoA reductase inhibitors. Clarithromycin for example increases the plasma concentration of concomitantly administered simvastatin, atorvastatin, and pravastatin (Jacobson, 2004) . In the case of simvastatin and atorvastatin this drug-interaction can be explained by the inhibition of CYP3A4 which predominantly metabolizes these statins. Interestingly, pravastatin is one of the statins which is not metabolized by cytochromes in humans and which is excreted almost unchanged into bile or to a Interestingly, an in vivo interaction between rosuvastatin, a recently established HMG-CoA reductase inhibitor, and erythromycin does not appear (Cooper et al., 2003) . Rosuvastatin is a substrate of several OATP-family members (OATP1B1, OATP1B3, OATP2B1, OATP1A2) and also of the sodium dependent bile salt transporter NTCP (Ho et al., 2006; Schneck et al., 2004) and therefore, the uptake inhibition of OATP1B1 or OATP1B3 could be compensated by transport via alternative transporting proteins.
Published K i values for inhibition of the metabolizing enzyme CYP3A4 by clarithromycin, erythromycin, roxithromycin, and telithromycin are 30 µM, 13 µM, 72 µM, and 58 µM, respectively (Aventis-Pharmaceuticals, 2001; Polasek and Miners, 2006) . Interestingly, the determined IC 50 values for macrolide-induced OATP1B3 inhibition are in the same concentration range. In addition, azithromycin, which has a high K i value for CYP3A4 (Polasek and Miners, 2006 ) is the only macrolide showing neither uptake inhibition of OATP1B1-nor OATP1B3-mediated uptake.
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As drugs reach the portal vein directly after intestinal absorption, the drug concentration in portal venous blood is higher than in the systemic circulation. For calculation of the predicted maximum drug concentration at the inlet to the liver we used the method of Ito et al. (1998) taking into account the maximum plasma concentration in the systemic circulation, the single dosage, the absorbed fraction of the macrolide, the absorption rate and the hepatic blood flow rate [ values for inhibition of OATP1B3-mediated uptake. We therefore conclude that inhibition of drug transporters by macrolides / ketolides could be an additional mechanism for clinical relevant drug-drug interactions. Further studies are necessary to gain more inside into the molecular nature of this inhibition mechanism.
Taken together our data demonstrate that macrolides / ketolides can inhibit uptake of organic anions and drugs mediated by the OATP family members OATP1B1 and OATP1B3. This modification of uptake rates is a new mechanism of drug-drug interactions in addition to the hitherto known mechanism of drug-drug interactions due to the modification of metabolizing enzymes and efflux transporters. Based on our findings it is therefore of importance to gain more knowledge on the modification of uptake transporter function as additional mechanism underlying drug-drug interactions.
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